The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $559,269 in first-year total cost, median $279,635.
Most frequent study sections
- Arthritis and Musculoskeletal and Skin Diseases Clinical Trials Study Section [AMSC]2
Most frequent institutions
- MASSACHUSETTS GENERAL HOSPITAL1
- TUFTS MEDICAL CENTER1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Veverimer to decrease net acid excretion and bone resorption in adults with osteopenia: a dose-finding randomized controlled trial1R61AR085647-01 | CEGLIA, LISA | TUFTS MEDICAL CENTER, MA | $331,051 | AMSC |
| 2025 | SGLT2i As Novel Gout Care (SAVE-Care): A Randomized Controlled Trial1R61AR084188-01A1 | CHOI, HYON K | MASSACHUSETTS GENERAL HOSPITAL, MA | $228,218 | AMSC |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.